Advanced Accelerator Applications is a radiopharmaceutical company, develops, produces, and commercializes radiolabeled pharmaceuticals and diagnostic nuclear medicines in France and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of oncology through assessing glucose metabolism; DOPAVIEW, a PET tracer for diagnostic use with applications in neurology and oncology sectors; and FluoroChol, a PET tracer for detecting metastasis of prostate cancer and hepatocellular carcinoma. The company also offers single-photon emission computed tomography (SPECT) products comprising Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, a cardiac imaging agent for myocardial exploration, localization of parathyroid tissue, and breast cancer diagnosis; and Leukokit, a single-use medical device to carry out separation and labeling of autologous leukocytes. In addition, it offers NETSPOT, a kit for the preparation of gallium Ga 68 dotatate injection for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients using PET; SomaKit TOC, a kit for radiopharmaceutical preparation of gallium edotreotide solution; and Annexin V-128, a SPECT radiopharmaceutical product candidate for the imaging of apoptotic and necrotic lesions. Its products that are in clinical development comprise Lutathera, a Lu-177 labeled somatostatin analogue peptide that has been approved for the treatment of neuro endocrine tumors; PSMA-R2, a selective PSMA-targeted ligand for prostate cancer; and NeoBOMB1, an antagonist bombesin analogue targeting GRPR-expressing malignancies. The company serves public and private hospitals, universities, third-party research laboratories, clinical centers, and pharmaceutical companies.
Advanced Accelerator Applications has 440 Twitter Followers. The number of followers has increased 6% month over month and increased 9.7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Advanced Accelerator Applications founded?
Advanced Accelerator Applications was founded in 2002.
Who are Advanced Accelerator Applications key executives?
Advanced Accelerator Applications's key executives are Stefano Buono, Heinz Mausli and Gerard Ber.
Who are Advanced Accelerator Applications competitors?
Competitors of Advanced Accelerator Applications include Source Bioscience, ImmuPharma and Assertio Therapeutics.
Where is Advanced Accelerator Applications headquarters?
Advanced Accelerator Applications headquarters is located at 20 Rue Diesel, Saint-Genis-Pouilly.
Where are Advanced Accelerator Applications offices?
Advanced Accelerator Applications has an office in Saint-Genis-Pouilly.
How many offices does Advanced Accelerator Applications have?
Advanced Accelerator Applications has 1 office.
Receive alerts for 300+ data fields across thousands of companies